QCM
ALNY icon

QRG Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

QRG Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$798K Buy
2,652
+375
+16% +$113K 0.01% 708
2026
Q1 		$754K Sell
2,277
-86
-4% -$29.3K 0.01% 660
2025
Q4 		$940K Sell
2,363
-72
-3% -$31.9K 0.01% 557
2025
Q3 		$1.11M Buy
2,435
+299
+14% +$122K 0.01% 505
2025
Q2 		$697K Buy
2,136
+187
+10% +$51.7K 0.01% 715
2025
Q1 		$526K Buy
1,949
+964
+98% +$248K 0.01% 753
2024
Q4 		$232K Buy
985
+180
+22% +$47.3K ﹤0.01% 993
2024
Q3 		$221K Buy
+805
New +$210K ﹤0.01% 1009
2024
Q1 		– Sell
-1,101
Closed -$211K – 1062
2023
Q4 		$211K Buy
+1,101
New +$188K ﹤0.01% 973

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

QRG Capital Management's ALNY Position: Q2 2026 in Review

QRG Capital Management increased its Alnylam Pharmaceuticals (ALNY) stake by 16% in Q2 2026, buying an estimated $113K and bringing the position to 2,652 shares worth $798K. The position accounts for 0.01% of the portfolio, ranked #708.

QRG Capital Management first reported a position in ALNY in Q4 2023 and has held it in 9 quarters since. The position peaked at $1.11M in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • QRG Capital Management held 2,652 shares of Alnylam Pharmaceuticals worth $798K as of Q2 2026.
  • QRG Capital Management bought 375 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $113K.
  • Alnylam Pharmaceuticals made up 0.01% of QRG Capital Management's portfolio in Q2 2026, its #708 holding.
  • QRG Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • QRG Capital Management's Alnylam Pharmaceuticals position peaked at $1.11M in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.